

Amendments To The Claims

This listing of claims replaces all prior versions of claims in the application.

Claims 1-6 (Canceled)

Claim 7 (Currently Amended) A purified antibody or fragment thereof which specifically binds an isolated polypeptide consisting of the amino acid sequence of SEQ ID NO: 6 ~~but does not bind the polypeptide consisting of the amino acid sequence of SEQ ID NO: 2, wherein said antibody or fragment thereof specifically recognizes monocyte cells.~~

Claim 8 (Canceled)

Claim 9 (Previously Presented) The antibody of claim 7, wherein said antibody is a monoclonal antibody.

Claims 10-16 (Canceled)

Claim 17 (Previously Presented) A hybridoma that produces the antibody of claim 7.

Claim 18 (Previously Presented) The fragment of claim 7, wherein said fragment is a Fab, Fv or antibody half molecule.

Claim 19 (Previously Presented) The antibody or fragment thereof of claim 7, wherein said antibody or fragment thereof is bound to a solid support.

Claim 20 (Previously Presented) A pharmaceutical formulation comprising the antibody or fragment thereof of claim 7 and one or more pharmaceutically acceptable carriers.

Claim 21 (Previously Presented) The pharmaceutical formulation of claim 20, wherein said formulation is suitable for parenteral administration.

Claim 22 (Previously Presented) The pharmaceutical formulation of claim 21, wherein said parenteral administration is subcutaneous administration.

Claim 23 (Previously Presented) The pharmaceutical formulation of claim 21, wherein said parenteral administration is intravenous administration.

Claim 24 (Canceled)

Claim 25 (Previously Presented) The antibody or fragment thereof of claim 7, wherein said antibody or fragment thereof is a recombinant therapeutic antibody or fragment.

Claim 26 (Previously Presented) A pharmaceutical formulation comprising the antibody or fragment thereof of claim 25 and one or more pharmaceutically acceptable carriers.

Claim 27 (Previously Presented) The pharmaceutical formulation of claim 26, wherein said formulation is suitable for parenteral administration.

Claim 28 (Previously Presented) The pharmaceutical formulation of claim 27, wherein said parenteral administration is subcutaneous administration.

Claim 29 (Previously Presented) The pharmaceutical formulation of claim 27, wherein said parenteral administration is intravenous administration.

Claim 30 (Canceled)

Claims 31 (New) The antibody of claim 7, wherein said antibody or fragment thereof binds to a polypeptide comprising residues 195-205 of SEQ ID NO:6.